Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug 30;10(9):845.
doi: 10.3390/biology10090845.

Refining Adjuvant Therapy for Endometrial Cancer: New Standards and Perspectives

Alessandra Giustozzi  1 , Vanda Salutari  2 , Elena Giudice  1 , Lucia Musacchio  2 , Caterina Ricci  2 , Chiara Landolfo  2 , Maria Teresa Perri  1 , Giovanni Scambia  1   2 , Domenica Lorusso  1   2
Affiliations
Review

Refining Adjuvant Therapy for Endometrial Cancer: New Standards and Perspectives

Alessandra Giustozzi et al. Biology (Basel). .

Abstract

Endometrial carcinoma is the most frequent cancer of the reproductive female organs. Most endometrial cancers are diagnosed at early stage (75%). Treatment options depend on pathogenetic, histopathologic and clinical characteristic at the diagnosis. To improve patient management in the near future, recent research has focused on new molecular features; evidence has shown that these give a better definition of patient prognosis and can help in tailoring adjuvant treatments by identifying specific subgroups of patients whose tumors may benefit from specific therapeutic approaches. In this review, we will focus on current knowledge of adjuvant treatment of endometrial carcinoma, using a prognostic-risk group stratification based on pathogenetic, clinical and molecular features, and will take a look at the ongoing trials that will further change the therapeutic approach in coming years.

Keywords: endometrial carcinoma; guidelines; molecular markers; treatment.

PubMed Disclaimer

Conflict of interest statement

V.S. reports grants from Clovis Oncology, grants from TESARO, grants from GSK, grants from Astra Zeneca, grants from MSD, grants from PHARMAMAR, grants from EISAI, grants from ROCHE, outside the submitted work; G.S. reports personal fees from ROCHE, personal fees from Clovis Oncology, personal fees from Astra Zeneca, personal fees from PharmaMar, personal fees from Tesaro, outside the submitted work; D.L. reports grants from ROCHE, grants and personal fees from GSK, grants and personal fees from Clovis Oncology, grants and personal fees from MSD, grants from Incyte, grants and personal fees from PHARMAMAR, grants from IMMUNOGEN, grants and personal fees from GENMAB, personal fees from AMGEN, grants and personal fees from ASTRA ZENECA, outside the submitted work; A.G., E.G., L.M., C.R., C.L., M.T.P. have nothing to disclose. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

    1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Constantine G.D., Kessler G., Graham S., Goldstein S.R. Increased Incidence of Endometrial Cancer Following the Women’s Health Initiative: An Assessment of Risk Factors. J. Womens Health. 2019;28:237–243. doi: 10.1089/jwh.2018.6956. - DOI - PMC - PubMed
    1. Sant M., Chirlaque Lopez M.D., Agresti R., Sánchez Pérez M.J., Holleczek B., Bielska-Lasota M., Dimitrova N., Innos K., Katalinic A., Langseth H., et al. Survival of Women with Cancers of Breast and Genital Organs in Europe 1999–2007: Results of the EUROCARE-5 Study. Eur. J. Cancer. 2015;51:2191–2205. doi: 10.1016/j.ejca.2015.07.022. - DOI - PubMed
    1. Bokhman J.V. Two Pathogenetic Types of Endometrial Carcinoma. Gynecol. Oncol. 1983;15:10–17. doi: 10.1016/0090-8258(83)90111-7. - DOI - PubMed
    1. Lax S.F., Pizer E.S., Ronnett B.M., Kurman R.J. Comparison of Estrogen and Progesterone Receptor, Ki-67, and P53 Immunoreactivity in Uterine Endometrioid Carcinoma and Endometrioid Carcinoma with Squamous, Mucinous, Secretory, and Ciliated Cell Differentiation. Hum. Pathol. 1998;29:924–931. doi: 10.1016/S0046-8177(98)90197-6. - DOI - PubMed

LinkOut - more resources